Tactile Systems Technology, Inc. TCMD
- Market cap
- $518.5M
- P/E
- 20.7×
Follow TCMD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 14.37 | 27.04 | 40.62 | 29.47 | 18.49 | 6.28 | 9.70 | 11.12 | 8.61 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 22.29 | 37.88 | 73.24 | 76.63 | 70.19 | 64.53 | 21.62 | 26.11 | 21.10 | 30.24 |
High Price
|
|||
| 335 | 406 | 499 | 629 | 707 | 988 | 982 | 992 | 1,037 | 1,086 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 85 | 109 | 144 | 189 | 187 | 208 | 247 | 274 | 293 | 330 |
Revenue
|
|||
| 72.87% | 73.45% | 71.14% | 70.84% | 70.97% | 71.24% | 71.31% | 71.11% | 73.96% | 75.91% |
Gross Margin
|
|||
| 4 | 4 | 3 | 11 | (2) | (2) | (15) | 16 | 23 | 31 |
EBT
|
|||
| 5.10% | 3.83% | 2.42% | 5.87% | (1.21%) | (1.10%) | (6.27%) | 5.75% | 8.02% | 9.51% |
EBT Margin
|
|||
| 3 | 6 | 7 | 11 | (1) | (12) | (18) | 29 | 17 | 19 |
Net Income
|
|||
| 1 | 2 | 4 | 3 | 3 | 4 | 6 | 7 | 7 | 7 |
Depreciation
|
|||
| 9.49 | 6.30 | 7.88 | 10.02 | 9.67 | 10.55 | 12.30 | 11.97 | 12.27 | 14.41 |
Revenue/Sh
|
|||
| 0.18 | 0.34 | 0.36 | 0.58 | (0.03) | (0.60) | (0.89) | 1.24 | 0.71 | 0.83 |
Earnings/Sh
|
|||
| 0.79 | 0.24 | 0.49 | 0.13 | 0.14 | 0.13 | 0.26 | 1.56 | 1.70 | 1.87 |
Cash Flow/Sh
|
|||
| (0.09) | (0.22) | (0.52) | (0.32) | (0.12) | (0.12) | (0.10) | (0.11) | (0.10) | (0.11) |
Capex/Sh
|
|||
| 0.70 | 0.02 | (0.03) | (0.18) | 0.03 | 0.01 | 0.16 | 1.46 | 1.60 | 1.76 |
Free CF/Sh
|
|||
| 6.69 | 4.19 | 4.89 | 5.95 | 6.45 | 6.50 | 6.05 | 8.45 | 9.07 | 9.57 |
Book Value/Sh
|
|||
| 9 | 17 | 18 | 19 | 19 | 20 | 20 | 23 | 24 | 23 |
Shares
|
|||
| 297.35 | 87.00 | 124.05 | 116.40 | 0.00 | 0.00 | 0.00 | 11.81 | 24.47 | 34.12 |
PE Ratio
|
|||
| 1.66 | 4.70 | 5.78 | 6.74 | 4.65 | 1.80 | 0.96 | 1.19 | 1.40 | 2.01 |
PS Ratio
|
|||
| 2.35 | 7.05 | 9.31 | 11.34 | 6.97 | 2.93 | 1.96 | 1.69 | 1.89 | 3.03 |
PB Ratio
|
|||
| 1.16 | 4.30 | 5.46 | 6.54 | 4.44 | 1.86 | 1.00 | 1.01 | 1.10 | 1.78 |
EV/Sales
|
|||
| 15.86 | 1,261.97 | (1,457.41) | (356.23) | 1,650.65 | 1,399.75 | 74.44 | 8.31 | 8.48 | 14.55 |
EV/FCF
|
|||
| 7 | 4 | 9 | 3 | 3 | 3 | 5 | 36 | 41 | 43 |
Op' Cash Flow
|
|||
| (1) | (4) | (10) | (6) | (2) | (2) | (2) | (2) | (2) | (3) |
Capex
|
|||
| 6 | 0 | (1) | (3) | 1 | 0 | 3 | 33 | 38 | 40 |
FCF
|
|||
| 50 | 62 | 69 | 87 | 97 | 79 | 55 | 104 | 137 | 124 |
Working Cap'
|
|||
| 0 | 0 | 0 | 15 | 19 | 52 | 46 | 26 | 23 | — |
Total Debt
|
|||
| (42) | (44) | (46) | (38) | (39) | 11 | 8 | (49) | (86) | (99) |
Net Debt
|
|||
| 60 | 73 | 89 | 113 | 125 | 128 | 121 | 194 | 217 | 219 |
Sh' Equity
|
|||
| 2.94% | 7.21% | 6.77% | 8.48% | (0.38%) | (5.65%) | (7.16%) | 10.63% | 5.85% | 6.67% |
ROA
|
|||
| 14.88% | 8.44% | 4.31% | 8.83% | (2.65%) | (0.79%) | (6.17%) | 7.80% | 10.59% | 15.29% |
ROIC
|
|||
| 6.05% | 8.84% | 8.17% | 10.87% | (0.52%) | (9.34%) | (14.31%) | 18.10% | 8.27% | 8.77% |
ROE
|
|||
Tactile Systems Technology, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CERS Cerus Corporation | $524.0M | 0.0× | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $531.6M | 28.9× | Compare |
| MASS 908 Devices Inc. | $492.7M | 0.0× | Compare |
| SENS Senseonics Holdings, Inc. | $546.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PACB Pacific Biosciences of California, Inc. | $484.9M | 0.0× | Compare |
| DCTH Delcath Systems, Inc. | $558.0M | 1,560× | Compare |
| NPCE NeuroPace, Inc. | $479.5M | 0.0× | Compare |
| SGHT Sight Sciences, Inc. | $478.2M | 0.0× | Compare |
Tactile Systems Technology, Inc. (TCMD) key facts
- Tactile Systems Technology, Inc. (TCMD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Tactile Systems Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $329.5 million, up 12.5% from fiscal 2024.
- Net income was $19.1 million, or $0.83 per share (basic), a net margin of 5.79%.
- As of September 25, 2026, TCMD traded at $22.73, a market capitalization of $518.5 million.
- At that price the stock trades at 20.7× trailing-twelve-month earnings and 1.5× sales.
- Return on equity was 8.77% and debt-to-equity 0.00.
Tactile Systems Technology, Inc. (TCMD) Latest News
17 Aug
Tactile Systems Technology, Inc. held its Q2 2026 earnings call to review financial results and business outlook. Quarterly earnings disclosure supplies performance metrics that can shift near-term investor sentiment and operational focus.
11 Aug
Tactile Systems Technology, Inc. (TCMD) held its Q2 2026 earnings call covering financial results and outlook. Earnings call updates typically affect near-term sentiment and valuation without major strategic shifts.
10 Aug
Tactile Systems Technology, Inc. reported its second quarter 2026 financial results. Quarterly financial results directly shape investor views and valuation for Tactile Systems Technology.
Tactile Systems Technology reported Q2 revenue growth driven by increased adoption of its lymphedema and chronic venous insufficiency therapies, with management highlighting expanded reimbursement coverage, new product pipeline progress, and raised full-year guidance amid steady operating margins. Quarterly earnings updates and guidance revisions typically produce moderate short-term share price movement without fundamentally changing long-term competitive positioning.
13 Jul
Tactile Medical entered an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device targeted at VA and DoD patients. Partnership expands device access in VA and DoD channels but does not alter core operations or market trajectory.
2 Jun
Tactile Medical launched next-generation AffloVest airway clearance therapy device. Next-generation AffloVest launch strengthens core product portfolio and competitive position.
11 May
Tactile Systems Technology (NASDAQ:TCMD) reported high-quality earnings that should please shareholders. High-quality earnings signal strong financial health and positively impact investor sentiment and market performance.
7 May
Tactile Systems Technology, Inc. (NASDAQ:TCMD) released first-quarter earnings, prompting analysts to share their views on the results. Quarterly earnings releases and analyst reactions often drive significant shifts in stock price, investor sentiment, and future performance expectations.
4 May
Tactile Systems Technology, Inc. (TCMD) released Q1 2026 earnings call summary detailing first-quarter financial results, operational updates, and forward-looking guidance. Q1 2026 earnings results and guidance significantly shape TCMD's financial outlook and investor expectations.
Tactile Systems Technology (TCMD) Q1 earnings call highlights financial results, revenue growth in lymphedema products, raised full-year guidance, and emphasized vascular franchise expansion amid strong demand. Q1 earnings beats, raised guidance, and product momentum signal significant positive trajectory for financial performance and investor sentiment.
Tactile Systems Technology (TCMD) Q1 2026 earnings call transcript covers quarterly financial results, revenue growth, product pipeline updates, and forward guidance amid lymphedema and vascular disease market dynamics. Q1 2026 earnings results, guidance, and strategic updates significantly influence TCMD's valuation, investor sentiment, and competitive positioning.
Tactile Systems Technology (TCMD) Q2 2025 earnings call transcript covers financial results, revenue growth, profitability metrics, product updates, and forward guidance. Q2 2025 earnings results, guidance, and strategic insights directly shape TCMD's financial trajectory and investor sentiment.
Tactile Systems Technology, Inc. (TCMD) released Q1 2025 earnings call transcript detailing financial results, performance highlights, and management commentary. Q1 earnings transcript discloses financial results and guidance that significantly influence TCMD's trajectory and investor sentiment.
Tactile Systems Technology, Inc. (TCMD) reported first quarter 2026 financial results. Quarterly earnings reports directly shape financial performance views and investor sentiment.
Tactile Systems Technology (TCMD) reported a Q1 net loss but exceeded revenue estimates. Q1 loss despite revenue beat moderately influences TCMD's financial performance and investor sentiment.
9 Apr
Tactile Systems Technology (TCMD) experiences a shifting narrative after Q4 results and 2026 guidance, highlighting changes in outlook and market perception. Q4 results combined with 2026 guidance represent major shifts that could significantly alter TCMD's trajectory and investor sentiment.
26 Feb
Wall Street analysts predict Tactile Systems Technology (TCMD) stock could surge 28.34%. Analysts' 28.34% upside forecast for TCMD signals moderately noticeable positive influence on investor sentiment and market performance.
25 Feb
Tactile Systems Technology (TCMD) narrative shifts positively after Q4 results and new analyst price targets. Q4 earnings and elevated analyst targets indicate major positive momentum for TCMD's trajectory and investor sentiment.
24 Feb
Tactile Systems Technology, Inc. (TCMD) reports 12% revenue growth to $329.5 million for 2025. 12% revenue growth to $329.5M indicates strong financial momentum likely to boost investor sentiment and enhance TCMD's market performance.
19 Feb
Tactile Systems Technology (TCMD) shares surged 19.7% after strong Q4 results, positive 2026 outlook, and LymphaTech deal. Strong Q4 earnings, optimistic 2026 guidance, and strategic LymphaTech deal signal major positive shift in financial trajectory and investor sentiment.
18 Feb
Tactile Systems Technology (TCMD) stock surged nearly 18% after reporting Q2 revenue of $58.3 million, up 19% year-over-year, adjusted EBITDA of $11.7 million, and raising full-year revenue guidance to $225-$228 million. Strong Q2 beat and raised FY guidance indicate significant positive shift in financial trajectory and investor sentiment.
Tactile Systems Technology Inc (TCMD) reported strong revenue growth in Q4 2025 earnings call highlights, driven by robust performance in core operations. Strong Q4 2025 revenue growth signals major positive shift in financial trajectory and investor confidence for TCMD.
Tactile Systems Technology, Inc. (TCMD) released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook. Q4 earnings summary impacts financial performance and investor sentiment moderately.
17 Feb
Tactile Systems Technology, Inc. (TCMD) released Q4 earnings call highlights, detailing financial results, revenue growth, profitability improvements, product updates, and forward guidance amid lymphedema and respiratory market expansions. Q4 earnings highlights disclose critical financial outcomes and strategic direction influencing near-term market performance and investor outlook.
Tactile Systems Technology (TCMD) reported Q4 earnings and revenues that topped analyst estimates. Q4 earnings and revenue beats represent significant positive financial results poised to enhance investor sentiment and stock performance.
Tactile Systems Technology, Inc. (TCMD) released Q4 earnings snapshot reporting key financial results including revenue, net income, and EPS compared to expectations and prior year. Q4 earnings snapshots reveal critical financial metrics that drive stock volatility and shape investor expectations for future performance.
Tactile Systems Technology, Inc. (TCMD) reported fourth quarter and full year 2025 financial results. Quarterly and annual earnings disclosures significantly shape investor sentiment, valuation, and future performance expectations.
Tactile Medical acquires LymphaTech to expand the breadth and depth of its lymphedema solutions portfolio. Acquiring LymphaTech bolsters TCMD's core lymphedema offerings, enhancing competitive positioning and growth potential.
8 Feb
Tactile Systems Technology, Inc. (TCMD) is experiencing a positive trend in returns, indicating potential growth and improved market performance. The company is likely benefiting from strategic initiatives and market dynamics that favor its operations. Investors may find this upward trajectory encouraging as it suggests a strengthening competitive position and financial outlook. The upward trend in returns suggests significant strategic moves that could alter the company's trajectory and investor sentiment.
25 Jan
Tactile Systems Technology, Inc. (TCMD) has reset its price target, prompting a reevaluation of its investment narrative. Analysts are adjusting their expectations based on recent performance and market conditions, which may influence investor sentiment and future stock performance. The company is navigating challenges while aiming for growth in its core business areas. The price target reset indicates a moderate shift in investor expectations that could influence TCMD's financial performance and market positioning.